These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 540209)

  • 1. Neuroendocrine effects of apomorphine: characterization of response patterns and application to schizophrenia research.
    Rotrosen J; Angrist B; Gershon S; Paquin J; Branchey L; Oleshansky M; Halpern F; Sachar EJ
    Br J Psychiatry; 1979 Nov; 135():444-56. PubMed ID: 540209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dopamine receptor alteration in schizophrenia: neuroendocrine evidence.
    Rotrosen J; Angrist BM; Gershon S; Sachar EJ; Halpern FS
    Psychopharmacology (Berl); 1976 Dec; 51(1):1-7. PubMed ID: 827770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroendocrine effects of apomorphine in chronic schizophrenic patients under long-term neuroleptic therapy and after drug withdrawal: relations to psychopathology and tardive dyskinesia.
    Müller-Spahn F; Ackenheil M; Albus M; May G; Naber D; Welter D; Zander K
    Psychopharmacology (Berl); 1984; 84(3):436-40. PubMed ID: 6151210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of apomorphine on growth hormone and prolactin secretion in schizophrenic patients, with or without oral dyskinesia, withdrawn from chronic neuroleptic therapy.
    Ettigi P; Nair NP; Lal S; Cervantes P; Guyda H
    J Neurol Neurosurg Psychiatry; 1976 Sep; 39(9):870-6. PubMed ID: 993808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of morphine on the serum prolactin levels of morphine-tolerant and nontolerant male rats and of the in vitro release of pituitary prolactin.
    Muraki T; Tokunaga Y
    Jpn J Pharmacol; 1978 Dec; 28(6):803-10. PubMed ID: 745306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apomorphine and schizophrenia. Treatment, CSF, and neuroendocrine responses.
    Levy MI; Davis BM; Mohs RC; Kendler KS; Mathé AA; Trigos G; Horvath TB; Davis KL
    Arch Gen Psychiatry; 1984 May; 41(5):520-4. PubMed ID: 6372737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endocrine responses to tryptophan infusion in schizophrenic patients treated with neuroleptics.
    Kolakowska T; Cowen PJ; Murdock P
    Psychoneuroendocrinology; 1987; 12(3):193-202. PubMed ID: 2887003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of apomorphine on blood levels of homovanillic acid, growth hormone and prolactin in medicated schizophrenics and healthy control subjects.
    Scheinin M; Syvälahti EK; Hietala J; Huupponen R; Pihlajamäki K; Seppälä OP; Säkö E
    Prog Neuropsychopharmacol Biol Psychiatry; 1985; 9(4):441-9. PubMed ID: 2866563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The blunted plasma cortisol response to apomorphine and its relationship to treatment response in patients with schizophrenia.
    Meltzer HY; Lee MA; Jayathilake K
    Neuropsychopharmacology; 2001 Mar; 24(3):278-90. PubMed ID: 11166518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential effects of dopamine agonists and haloperidol on release of prolactin, thyroid stimulating hormone, growth hormone and luteinizing hormone in rats.
    Mueller GP; Simpkins J; Meites J; Moore KE
    Neuroendocrinology; 1976; 20(2):121-35. PubMed ID: 958594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth hormone and prolactin response to apomorphine in schizophrenia and the major affective disorders. Relation to duration of illness and depressive symptoms.
    Meltzer HY; Kolakowska T; Fang VS; Fogg L; Robertson A; Lewine R; Strahilevitz M; Busch D
    Arch Gen Psychiatry; 1984 May; 41(5):512-9. PubMed ID: 6721674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hormonal effects of apomorphine in schizophrenia.
    Ferrier IN; Johnstone EC; Crow TJ
    Br J Psychiatry; 1984 Apr; 144():349-57. PubMed ID: 6722395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppressive effect of cyproheptadine on L-DOPA-induced growth hormone release in man.
    Nakai Y; Imura H
    Endocrinol Jpn; 1975 Aug; 22(4):357-60. PubMed ID: 1201741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CCK-33 antagonizes apomorphine-induced growth hormone secretion and increases basal prolactin levels in man.
    Nair NP; Lal S; Thavundayil JX; Wood PL; Etienne P; Guyda H
    Neuropeptides; 1984 Jun; 4(4):281-91. PubMed ID: 6472582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adenohypophysial dopamine content and prolactin secretion in the aged male and female rat.
    Demarest KT; Moore KE; Riegle GD
    Endocrinology; 1985 Apr; 116(4):1316-23. PubMed ID: 3971917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Down-regulation of central dopamine receptors in schizophrenia.
    Zemlan FP; Hitzemann RJ; Hirschowitz J; Garver DL
    Am J Psychiatry; 1985 Nov; 142(11):1334-7. PubMed ID: 2865903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hormones, dopamine receptors and schizophrenia.
    Meltzer HY; Busch D; Fang VS
    Psychoneuroendocrinology; 1981; 6(1):17-36. PubMed ID: 7244055
    [No Abstract]   [Full Text] [Related]  

  • 18. A neuroendocrine study of supersensitivity in tardive dyskinesia.
    Tamminga CA; Smith RC; Pandey G; Frohman LA; Davis JM
    Arch Gen Psychiatry; 1977 Oct; 34(10):1199-203. PubMed ID: 911219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The mechanism of action of cyproheptadine on prolactin release by cultured anterior pituitary cells.
    Lamberts SW; Verleun T; Oosterom R
    Life Sci; 1985 Jun; 36(23):2257-62. PubMed ID: 3923287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug-induced growth hormone and prolactin responses in schizophrenia research.
    Lal S; Nair NP; Iskandar HI; Thavundayil JX; Etienne P; Wood PL; Guyda H
    Prog Neuropsychopharmacol Biol Psychiatry; 1982; 6(4-6):631-7. PubMed ID: 6131495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.